Your browser doesn't support javascript.
loading
Adverse Events After MMR or MMRV Vaccine in Infants Under Nine Months Old.
Woo, Emily Jane; Winiecki, Scott K; Arya, Deepa; Beeler, Judy.
Afiliación
  • Woo EJ; From the *Office of Biostatistics and Epidemiology and †Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Pediatr Infect Dis J ; 35(8): e253-7, 2016 08.
Article en En | MEDLINE | ID: mdl-27167117
ABSTRACT

BACKGROUND:

In the United States, measles is resurging, with more than 700 confirmed cases since January 2014. During measles outbreaks, vaccination as early as at 6 months of age is sometimes recommended for infants who are at risk for exposure.

METHODS:

We searched the Vaccine Adverse Event Reporting System for reports of measles, mumps and rubella vaccine combined or measles, mumps, rubella and varicella vaccine combined vaccination in children less than 9 months of age. We performed a clinical assessment of each report and summarized the frequency, range, onset time and severity of adverse events.

RESULTS:

After excluding 346 reports because they were duplicates or because they contained insufficient information about the child's age or vaccine(s), we retained 204 reports in the analysis, including 35 (17%) that were serious. Among the 169 nonserious reports, more than half (88; 52%) described a vaccination error without any adverse event per se. Other nonserious reports described fever, injection reactions and gastrointestinal symptoms. Serious adverse events included developmental disorders, fever and fussiness. There were 44 reports of fever, but only 4 cases began 5-12 days after immunization, the peak risk window. The vast majority of fever reports listed concomitant vaccines, such as diphtheria and tetanus toxoids, acellular or whole-cell pertussis vaccine.

CONCLUSIONS:

This review did not identify any major safety concerns. These findings may facilitate discussions about the risks and benefits of vaccinating infants who are potentially exposed to this life-threatening disease.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacuna contra la Varicela / Vacuna contra el Sarampión-Parotiditis-Rubéola / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos Tipo de estudio: Prognostic_studies Límite: Female / Humans / Infant / Male / Newborn País/Región como asunto: America do norte Idioma: En Revista: Pediatr Infect Dis J Asunto de la revista: DOENCAS TRANSMISSIVEIS / PEDIATRIA Año: 2016 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacuna contra la Varicela / Vacuna contra el Sarampión-Parotiditis-Rubéola / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos Tipo de estudio: Prognostic_studies Límite: Female / Humans / Infant / Male / Newborn País/Región como asunto: America do norte Idioma: En Revista: Pediatr Infect Dis J Asunto de la revista: DOENCAS TRANSMISSIVEIS / PEDIATRIA Año: 2016 Tipo del documento: Article